Welcome to the August 2025 episode of DiabetesBio—the American Diabetes Association’s podcast for its flagship research publication, Diabetes. In this episode of DiabetesBio, Drs. Kirk Habegger, Darleen Sandoval, and Kevin Williams discuss the latest and greatest content in the August 2025 issue of Diabetes.

6:55 For this month’s episode, a special extended edition of “Sweet Talk,” exploring the debate about whether GIP receptor agonism or GIP receptor antagonism holds the most promise for therapeutic strategies. First, our hosts are joined by Daniel J. Drucker, OC, MD, FRCPC, FRSC, FRS, recipient of the American Diabetes Association’s (ADA) 2014 Banting Medal for Scienfitic Achievement for his research with GLP-1s. They also speak with Jonathan Campbell, PhD, Associate Professor in Medicine at the Duke Molecular Physiology Institute at Duke University. They discuss the history of endocrine biology research and their article, “Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies,” available for free at doi.org/10.2337/db25-0393.

42:00 As the conversation continues, our guests discuss the controversy of the GIP receptor agonism, antagonism debate. These arguments are highlighted in a special debate series in the August issue of Diabetes, featuring a point article, “A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity,” available for free at doi.org/10.2337/dbi24-0026, and a counterpoint article titled “GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale,” also available for free at doi.org/10.2337/dbi24-0027.

And don’t forget to reach out! Let us know your stance in the debate between agonism and antagonism, and share your favorite science-related podcasts!

To learn more about Diabetes and DiabetesBio, please visit diabetesjournals.org/diabetes. Thank you for listening, and don’t forget to smash that “follow” button!

A special extended “Sweet Talk” episode on the debate between GIP receptor agonism and GIP receptor antagonism, with Daniel Drucker, OC, MD, FRCPC, FRSC, FRS, and Jonathan Campbell, PhD.

DiabetesBio